Attempt Compounding Pharmacy has filed a federal antitrust lawsuit towards Eli Lilly and Novo Nordisk, alleging a coordinated effort to suppress competitors and prohibit affected person entry to lawful compounded GLP-1 medicines.
The criticism, filed on January 14, 2026, in the US District Courtroom for the Western District of Texas, alleges that the pharmaceutical producers used their dominant market positions to undermine the compounding pharmacy trade by discouraging suppliers, telehealth platforms, and sufferers from prescribing and accessing compounded GLP-1 medicines.
GLP-1 receptor agonists are extensively prescribed for metabolic illness and weight administration. When business merchandise are unavailable or clinically unsuitable, compounding pharmacies might put together personalized formulations below federal and state regulatory oversight, permitting prescribing selections to stay between physicians and sufferers.
Compounding pharmacies serve a lawful and established position throughout the U.S. healthcare system by getting ready personalized medicines for sufferers whose wants can’t be met by mass-produced medication or in periods of drug scarcity.
“For us, that is greater than only a enterprise dispute; it’s a battle for the suitable of each affected person to have entry to the drugs their physician prescribes, at a worth that isn’t dictated by a monopoly,” stated Nate Hill, Co-Founder and CEO of Attempt Compounding Pharmacy.l
“We’re standing up to make sure that medical judgment stays between a health care provider and their affected person, not a pharmaceutical government and a steadiness sheet. Truthful competitors is important to this trade and the broader economic system. With out it, entry vanishes and costs rise. By submitting this lawsuit, we’re defending a lawful trade that tens of millions of People depend on.”
Attempt is represented by BakerHostetler. The case is Attempt Specialties Inc. v. Eli Lilly & Co. et al., filed in the US District Courtroom for the Western District of Texas.
The complete criticism is offered at: https://www.strivepharmacy.com/antitrustlawsuit